Ionis Pharmaceuticals IONS Accrued Commercial Expenses Current
Accrued Commercial Expenses Current at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:AccruedCommercialExpensesCurrent.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's accrued commercial expenses current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's accrued commercial expenses current?
- Ionis Pharmaceuticals (IONS) reported accrued commercial expenses current of $40.47M in Q1 2026.
- How has Ionis Pharmaceuticals's accrued commercial expenses current changed year-over-year?
- Ionis Pharmaceuticals's accrued commercial expenses current increased by 457.6% year-over-year, from $7.26M to $40.47M.
- What is the long-term trend for Ionis Pharmaceuticals's accrued commercial expenses current?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's accrued commercial expenses current has grown at a 58.4% compound annual growth rate (CAGR), from $2.47M to $15.56M.
- What does accrued commercial expenses current mean?
- Short-term unpaid costs related to selling and marketing products.
- How do you interpret accrued commercial expenses current?
- Rising accruals often reflect increased commercial activity, product launches, or expanded sales force efforts.
- How does accrued commercial expenses current compare across companies?
- Standard for commercial-stage pharmaceutical companies to track the operational costs of supporting product revenue.